Literature DB >> 7575665

Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells.

L A Hazlehurst1, A P Krapcho, M P Hacker.   

Abstract

Aza-anthracenediones are a new class of anti-cancer drugs, which demonstrate promising in vitro and in vivo activity. Our laboratory has synthesized a variety of structural analogs in which we determined previously that the positioning of the nitrogen within the backbone, as well as sidearm modification, results in dramatic differences in the potency of cytotoxicity. We reported previously that although DNA reactivity appears to be a necessary component for mediating cell death, it is not sufficient for predicting cytotoxicity of the aza-anthracenediones. We have chosen three aza-anthracenediones (BBR 2828, BBR 2778 and BBR 2378) to investigate the importance of DNA strand breaks and/or protein-concealed DNA breaks induced by aza-anthracenediones. We determined in the present study that, while all three drugs cause DNA breaks as determined by alkaline and neutral elution, as well as KCl-SDS precipitation, these breaks do not correlate directly with their potency as cytotoxic compounds. Further, we found significant differences in the types of DNA breaks induced by these drugs. Finally, we report that the persistence of protein-DNA complexes induced by all three drugs was similar and, therefore, cannot account for differences in the potency of cytotoxicity of the aza-anthracenediones. Thus, we postulate that, while the total number of drug-induced protein-concealed DNA breaks is an important indicator of drug toxicity, it is possible that the actual nature of the breaks may differ among the aza-anthracenedione congeners, and it is these differences in the actual proteins present in the DNA breaks that differentiate between aza-anthracenediones.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575665     DOI: 10.1016/0006-2952(95)00246-v

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

Authors:  Raushan T Kurmasheva; C Patrick Reynolds; Min H Kang; Cecilia Allievi; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-10-26       Impact factor: 3.167

2.  Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.

Authors:  Brian B Hasinoff; Xing Wu; Daywin Patel; Ragu Kanagasabai; Soumendrakrishna Karmahapatra; Jack C Yalowich
Journal:  J Pharmacol Exp Ther       Date:  2015-12-11       Impact factor: 4.030

Review 3.  Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.

Authors:  Stefano Volpetti; Francesco Zaja; Renato Fanin
Journal:  Onco Targets Ther       Date:  2014-05-29       Impact factor: 4.147

4.  Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions.

Authors:  Neil Beeharry; Andrea Ghelli Luserna Di Rora; Mitchell R Smith; Timothy J Yen
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  Synthesis and antitumor evaluation of 6-aryl-substituted benzo[j]phenanthridine- and benzo[g]pyrimido[4,5-c]isoquinolinequinones.

Authors:  Jennyfer Iribarra; David Vásquez; Cristina Theoduloz; Julio Benites; David Ríos; Jaime A Valderrama
Journal:  Molecules       Date:  2012-09-28       Impact factor: 4.411

6.  CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity.

Authors:  Benny J Evison; Rebecca A Bilardi; Francis C K Chiu; Gabriella Pezzoni; Don R Phillips; Suzanne M Cutts
Journal:  Nucleic Acids Res       Date:  2009-08-31       Impact factor: 16.971

7.  Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.

Authors:  Ben J Evison; Oula C Mansour; Ernesto Menta; Don R Phillips; Suzanne M Cutts
Journal:  Nucleic Acids Res       Date:  2007-05-05       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.